Skip to main content
SpringerLink
Log in

Trial watch

The clinical trial landscape for PD1/PDL1 immune checkpoint inhibitors

  • Biobusiness Briefs
  • Published:

From Nature Reviews Drug Discovery

View current issue Sign up to alerts

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1: The clinical trial landscape for PD1/PDL1 immune checkpoint inhibitors.
Figure 2: Recruitment rates for trials involving anti-PD1/PDL1 therapies.

Acknowledgements

The authors thank D. Patel from IQVIA for supporting this report.

Author information

Authors and Affiliations

  1. Anna-Maria Kellen Clinical Accelerator, Cancer Research Institute, New York, NY, USA

    Jun Tang, Jia Xin Yu & Vanessa M. Hubbard-Lucey

  2. IQVIA, Durham, NC, USA

    Svetoslav T. Neftelinov, Jeffrey P. Hodge & Yunqing Lin

Authors
  1. Jun Tang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jia Xin Yu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Vanessa M. Hubbard-Lucey
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Svetoslav T. Neftelinov
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jeffrey P. Hodge
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yunqing Lin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jun Tang.

Ethics declarations

Competing interests

JT, JXY, and VHL are employees of Cancer Research Institute and claim no conflicts of interests.

STN, JPH, YL and DP are employees of IQVIA and claim no conflicts of interests.

Supplementary information

Supplementary information

Supplementary information S1 (figure) (PDF 577 kb)

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Tang, J., Yu, J., Hubbard-Lucey, V. et al. The clinical trial landscape for PD1/PDL1 immune checkpoint inhibitors. Nat Rev Drug Discov 17, 854–855 (2018). https://doi.org/10.1038/nrd.2018.210

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd.2018.210

  • Springer Nature Limited

This article is cited by

Search

Navigation